BioSenic Secures Key Japanese Patent for Enhanced Arsenic-Based Therapeutics in Autoimmune and Cancer Treatments

Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration. Enriched IP portfoli...

August 14, 2024 | Wednesday | News
Shanghai Junshi Biosciences’ Toripalimab sNDA Accepted by NMPA for First-Line Treatment of Advanced Melanoma

Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of ...

August 13, 2024 | Tuesday | News
Angiex Initiates Phase 1 Trial of Innovative AGX101 Cancer Therapy with Abzena's Support

Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for...

August 09, 2024 | Friday | News
Angiex Initiates Phase 1 Clinical Trial for AGX101, a First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for Solid Tumors

Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for...

August 09, 2024 | Friday | News
Vertex Pharmaceuticals Secures Landmark Reimbursement Deal with NHS England for First CRISPR Gene-Edited Therapy

Vertex Pharmaceuticals (Nasdaq: VRTX) announced  a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT...

August 09, 2024 | Friday | News
Novartis' Fabhalta® Receives FDA Accelerated Approval for IgA Nephropathy Treatment

Novartis is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta® (iptacopan), a ground...

August 08, 2024 | Thursday | News
Thermo Fisher Scientific's SeCore™ CDx HLA A Sequencing System Receives FDA Clearance as Companion Diagnostic for Adaptimmune’s TECELRA® TCR Therapy

Thermo Fisher Scientific Inc., the world leader in serving science,  announced that its SeCore™ CDx HLA A Sequencing System has been granted 5...

August 07, 2024 | Wednesday | News
Daiichi Sankyo and MSD Expand Collaboration to Co-Develop and Co-Commercialize DLL3 T-Cell Engager MK-6070

Agreement builds on and complements Daiichi Sankyo and Merck’s shared commitment to develop novel medicines for patients with cancer Daiichi Sanky...

August 07, 2024 | Wednesday | News
Fifty 1 Labs and All-In-Extracts Announce Joint Venture for Innovative Testosterone-Boosting Supplement

Fifty 1 Labs, Inc. , a holding company that operates in the sports supplement, fitness equipment, and health and wellness industries, and All-In-Extracts...

August 06, 2024 | Tuesday | News
FDA Grants Accelerated Approval for TECELRA in Advanced Synovial Sarcoma Treatment

Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment ...

August 02, 2024 | Friday | News
Kiromic BioPharma Announces Promising Eight-Month Results from Deltacel-01 Phase 1 Trial

Kiromic BioPharma, reports favorable eight-month follow-up results from the first patient enrolled in its Deltacel-01 Phase 1 clinical trial. This trial ...

August 02, 2024 | Friday | News
MilliporeSigma Acquires Mirus Bio for $600 Million, Enhancing Viral Vector Manufacturing Capabilities

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leadin...

August 02, 2024 | Friday | News
Molecure and Avicenna Biosciences Announce Strategic Collaboration to Develop Novel Cancer Therapies Targeting USP7

Molecure S.A. (‘Molecure’, SWE Ticker: MOC) and Avicenna Biosciences, Inc. announced today that they have entered into a strategic research c...

August 01, 2024 | Thursday | News
AbCellera Expands Collaboration with Eli Lilly to Develop Therapeutic Antibodies Across Multiple Therapeutic Areas

AbCellera (Nasdaq: ABCL) announcedthat it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies f...

August 01, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close